Ads
related to: breast cancer, hormones- Overall Survival Results
See Updated Overall Survival Data
For This Treatment Option
- Dosing & Administration
Read More About Dosing
And How To Prescribe
- Patient Support
View The The Service Request Form
To Gain Access To Support Programs
- Official Video Library
See A Medical Expert Discuss
Overall Survival Data For mBC
- Financial Resources
Learn About The Available Access
Programs For Your Patients
- Safety Profile
View The Full Safety Profile And
See Side Effects For This Option
- Overall Survival Results
Search results
Girls are getting their first periods earlier. Here's what parents should know
WLRN Miami· 13 hours agoGirls in the U.S. are getting their first menstrual period about 6 months earlier on average than...
FoxConn places it focus on the health of women
Tribune Chronicle· 13 hours agoDenise Huemme was 35 when she was diagnosed with breast cancer — the first time. Sixteen years later, she is still a survivor and wants her coworkers at...
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
Zacks via Yahoo Finance· 4 hours agoJ&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority...
PKMYT1, a potential 'Achilles heel' of treatment resistant ER+ breast cancers with the poorest...
Medical Xpress· 7 days agoLooking to identify new vulnerabilities in this type of cancer that could lead to improved...
Promising New Treatment for Patients with HR+ HER- | Newswise
Newswise· 2 days agoBreast cancer that has spread to other parts of the body (metastatic) is particularly hard to treat. New research from Yale Cancer Center ...
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in...
WTNH-TV New Haven· 3 days agoDuring the quarter, the Company completed its landmark ICE3 trial and recently achieved several objectives, including: publishing and submitting the full data set of its ICE3 trial results to ...
Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag
Zacks· 3 days agoThe FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Susan's Battle: How Personal Health Literacy and Technology Empowered Her Breast Cancer Journey
USA Today· 2 days agoWhen Susan Tsiaras received the devastating news that she had breast cancer, she knew her journey...
Dietician goes viral by debunking food myths about cancer - Dexerto
Dexerto· 8 hours agoAn oncology dietician has gone viral on TikTok after she revealed the two foods you should avoid if...
Stifel maintains $40 target on Celcuity, cites trial potential By Investing.com
Investing.com· 23 hours agoThe firm's analyst highlighted the potential market opportunity for Celcuity's gedatolisib in...
Ad
related to: breast cancer, hormones
